BioConvergence for Health (BioConvS) is a major research and innovation program (DIM) of the Île-de-France Region, which aims to strengthen the research communities in synthetic biology, biotherapy, and bioproduction, to facilitate the transition from scientific excellence to innovation, and to position the Île-de-France Region as a global leader in this field.

BioConvS is led by Université Paris Cité in partnership with Sorbonne University, Institut Curie - PSL, Institut Micalis (INRAe, AgroParisTech, Université Paris-Saclay), INSERM, Généthon, Génopole, and other institutions. BioConvS brings together stakeholders from both the public and private sectors and receives up to €12.5 million in funding from the Île-de-France Region for the duration of the 2022-2026 funding period. More details about the BioConvS DIM are available at: https://bioconvs.org/

This equipment funding call for proposals from the DIM BioconvS program is open from February 2, 2026 to June 1, 2026, with a projected budget of approximately €1 million to finance the purchase of equipment. The equipment will be funded by the Île-de-France Region, with a maximum funding rate of 66% of the total cost (excluding VAT). A co-funding contribution of 34% must therefore be included in the funding application.

Each principal investigator may submit only one application for funding, which must be for equipment with a total cost of at least €7,500 (resulting in a grant of at least €4,950).

The grant amount decided by the DIM is a maximum amount: actual expenses (based on submitted invoices) will be reimbursed up to the funding rate, up to the total grant amount. For example, if the actual expenses for an item of equipment are €37,879 (excluding VAT) with a funding rate of 66%, the grant amount will be €25,000.

BioconvS website

Join our LinkedIn group

Follow our LinkedIn page

Qu'est-ce que c'est un DIM?